Evaluate the expected performance of Haemonetics (HAE) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Haemonetics' (NYSE:HAE) stock is up by a considerable 12% over the past month. Given the company's impressive...